Page 319 - Drug Class Review

Drug Effectiveness Review Project

rivastigmine placebo N/A N/A Significant differences in the odds ratios (AEs RIV/AEs placebo) were noted across concomitant use of anticholinergics, diabetic drugs, cardiac drugs, diuretics, estrogens, salicylic acid, psycholeptics, and aldehydes and derivatives ITT: NR Post randomization exclusions: NR NR NR NR Overall loss to follow-up: NR Loss to follow-up differential high: NR placebo rivastigmine NR NR NR NR N/A Page 190 of 205

Final Report Update 1 Authors: Grossberg et al Year: 2000 ADVERSE EVENTS: Overall adverse effects reported: N/A • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs